-
PANoptosis-Related Gene Signature Predicts Prognosis and Immune Status in Biliary Tract Cancer Patients
Recent research has highlighted the crucial role of the tumor microenvironment in BTC progression and invasiveness. The primary goal of cancer therapy is to disrupt tumor cells, and a key…
-
CID’s Most-Read Article: “Miracle Drug” Metformin Significantly Reduces Viral Load in Outpatient COVID-19 Patients!
Metformin has demonstrated antiviral activity against RNA viruses, including SARS-CoV-2. The drug’s mechanism appears to involve targeting the host’s mTOR pathway to inhibit protein translation. The COVID-OUT trial was a…
-
IDWeek丨Cutting-Edge Progress in HIV Prevention and Treatment: New Drugs and Innovative Diagnostic Technologies
Implementation of Long-Acting Antiretroviral Therapy and Prevention In the realm of HIV prevention and treatment, long-acting antiretroviral drugs have made groundbreaking progress: The implementation of long-acting regimens requires careful consideration…
-
News Express | Physical Function Changes in Pediatric Patients Before and After Hematopoietic Stem Cell Transplantation
The “News Express” column aims to bridge the gap between cutting-edge research and clinical practice, allowing every hematology enthusiast and professional to quickly capture industry trends, spark innovative thinking, and broaden professional horizons. Hematology Frontier carefully selects the latest hematology research findings from top global journals, delivering every brilliant spark of science and clinical practice…
-
Dr. Jianyong Li: Advances in Research on Nodal T-Follicular Helper Cell Lymphoma (nTFHL)
Angioimmunoblastic T-cell lymphoma (AITL), as a major subtype of peripheral T-cell lymphoma (PTCL), poses significant challenges for clinicians due to its complex pathological features, variable clinical presentation, and poor prognosis. In recent years, with advances in medical research, novel diagnostic techniques and treatment methods for nTFHL have emerged, leading to new breakthroughs in diagnosis and…
-
Dr. Wenbin Qian: Analyzing the Pros and Cons of CAR-NK Therapy and Future Research Directions
In the realm of cellular therapy, CAR-NK technology is spearheading a new wave of treatment possibilities. Given the current state of cellular therapy in China, advancing technologies like CAR-NK has become crucial. At the 12th Lu Daopei Hematology Forum, Hematology Frontier had the privilege of inviting Dr. Wenbin Qian from The Second Affiliated Hospital Zhejiang…
-
Dr. Shenmiao Yang: Navigating the New Era of CLL Treatment with Long-Term and Short-Term Approaches
With the widespread adoption of chemotherapy-free treatment regimens and breakthroughs in targeted therapies, chronic lymphocytic leukemia (CLL) treatment has entered a new era. At the 12th Lu Daopei Hematology Forum, Hematology Frontier invited Dr. Shenmiao Yang from Peking University People’s Hospital to provide an in-depth analysis of the current state of CLL treatment in China,…
-
Dr. Jun Zhu: Advancing Lymphoma Drug Development in China to Propel the Discipline and Hospital Growth
Under the leadership of Dr. Jun Zhu, the Lymphoma Department at Peking Cancer Hospital has become a frontrunner in lymphoma drug development. This year, what innovative achievements from the team will illuminate the treatment path for lymphoma patients? How have they showcased Chinese expertise on the international stage? Additionally, how will the opportunities and challenges…
Connecting Medical Expertise through Media